Paliperidone 3-monthly and 6-monthly Long Acting Injectables in Schizophrenia – Key Points

Posted on: August 23, 2022
Last Updated: August 23, 2022

Welcome to the Fifteenth Edition of the GP Mental Health Bites!

This month’s edition of GP Mental Health Bites informs on what you, as a GP, need to know about Paliperidone 3-monthly and 6-monthly long-acting injectables in the management of schizophrenia.  (LAIs).

In this video, we review:

  • The availability of long-acting injectable paliperidone formulations
  • The benefits of longer-acting injectable antipsychotics
  • Data on 6-monthly compared to 3-monthly paliperidone LAIs
  • Who is the ideal patient for a longer-acting injectable antipsychotic?

The video provides advice on how to identify patients who may be more suited to a longer-acting injectable antipsychotic, enabling timely referral to the treating psychiatrist for transition to a longer-acting therapy.

Rate this video